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ABSTRACT 
Fibroblasts are central to wound healing and fibrosis 
through Transforming Growth Factor-β1 (TGF-β1)-
triggered differentiation into contractile, α-smooth 
muscle actin (α-sma)-positive myofibroblasts. This 
is mediated by accumulation of a pericellular matrix 
of hyaluronan (HA) and the HA-dependent co-
localisation of CD44 with the Epidermal Growth 
Factor Receptor (EGFR). Interactions of HA with 
hyaladherins, such as Inter-alpha-Inhibitor (IaI) and 
Tumour Necrosis Factor-stimulated gene-6 (TSG-6) 
are also essential for differentiation. This study 
investigated the mechanisms involved.   TSG-6 and 
α-sma had different kinetics of induction by TGF-
β1, with TSG-6 peaking before α-sma.  siCD44 or 
EGFR inhibition prevented differentiation but had 
no effect on TSG-6 expression. TSG-6 was essential 
for differentiation, and mAb A38 (preventing IαI 
heavy chain [HC] transfer), HA-oligosaccharides, 
Cobalt, or siBikunin prevented TSG-6 activity, 
preventing differentiation. A38 also prevented the 
EGFR/CD44 association.  This suggested that TSG-
6/IαIHC interaction was necessary for the effect of 
TSG-6 and that HC-stabilisation of HA initiated the 
CD44/EGF-R association. The newly-described 
HC5 was shown to be the principal HC expressed 
and its cell surface expression was prevented by 
siRNA inhibition of TSG-6 or Bikunin.  HC5 was 
released by hyaluronidase treatment, confirming its 
association with cell surface HA. Finally, HC5 
knock down by siRNA confirmed its role in 
myofibroblast differentiation. The current study 
describes a novel mechanism linking the TSG-6 
transfer of the newly-described HC5 to the HA-
dependent control of cell phenotype. The interaction 
of HC5 with cell surface HA was essential for TGF-
β1-dependent differentiation of fibroblasts to 
myofibroblasts, highlighting its importance as a 
novel potential therapeutic target. 
  
The fibroblast is the most abundant cell type in 
normal connective tissues.  It plays a central role in 
the synthesis, degradation and remodelling of 
extracellular matrix both in health and in disease. At 
sites of tissue damage and in the context of wound 
healing, activated fibroblasts, termed 
myofibroblasts, with a contractile phenotype, 
characterised by the expression of the smooth 
muscle isoform of α-actin (α-sma), are essential for 
the synthesis of a collagen-rich scar, providing the 
force for wound contraction (1). During a healing 
response, myofibroblasts are a transient cell 
population (2).  Myofibroblasts are also the major 
effectors of fibrosis, their persistent presence has 
been established as the best marker of numerous 
types of progressive organ dysfunction such as that 
seen in chronic renal failure of various aetiologies 
(3, 4, 5, 6, 7), liver disease (8) and pulmonary 
fibrosis (9).   
 http://www.jbc.org/cgi/doi/10.1074/jbc.M115.670521The latest version is at 
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The cytokine Transforming Growth Factor Beta-1 
(TGF-β1) is a well recognised mediator of 
progressive tissue fibrosis and in vitro and in vivo 
evidence suggest that it is the primary driving force 
in fibroblast-myofibroblast phenotypic activation 
(10, 11).  The sequence of events leading up to this 
transformation is being increasingly characterised at 
a molecular level in an attempt to understand and 
eventually control this process. 
We have previously demonstrated that TGF-β1-
mediated phenotypic activation is dependent on an 
increase in the synthesis of the extracellular matrix 
polysaccharide hyaluronan (HA) (12, 13, 14).  TGF-
β1, through stimulation of EGF and subsequent 
activation of EGFR-associated ERK-MAP kinase 
activity stimulates HA synthesis. This increased HA 
synthesis is associated with the formation of an 
organised pericellular HA coat which subsequently 
orchestrates assembly of a CD44/EGFR receptor 
complex on the cell surface.  Activation of ERK 
signalling downstream of this complex subsequently 
leads to a re-organisation of the actin cytoskeleton.  
The secreted product of Tumor Necrosis Factor-
stimulated Gene 6 (TSG-6) is important in the 
formation and remodelling of HA-rich pericellular 
coats and matrices (14, 15, 16,).  It is involved in the 
formation of TSG-6 cross-linked HA networks (17) 
and may also stabilise the HA matrix either by 
binding directly as a hyaladherin, or through 
facilitating the covalent transfer of heavy chains of 
inter-alpha-inhibitor (IαI) onto HA to form a 
HC/HA complex (18, 19).  Thus in the TGF-β1-
triggered generation of the myofibroblast 
phenotype, we proposed that TSG-6 may play an 
important part in forming the HA/CD44/EGFR 
complex, which then signals to induce ERK 
activation.  
The mechanism of heavy chain (HC) transfer has 
been elucidated by Rugg et al (19).  TSG-6 forms an 
intermediate species with one of the two heavy 
chains from the IαI complex, which consists of the 
light chain bikunin and its chrondroitin sulphate 
(CS) chain which is bound to 2 heavy chains.  
Classically, three HC’s have been described.  HC1 
and HC2 are known to occur bound to CS to form 
IaI, while HC3 is thought to bind CS/bikunin as a 
single chain forming an assembly known as pre-αI.  
Previous work (20) has shown that TSG-6 is capable 
of transferring not only HC2 but also HC1 and HC3 
from IαI (or pre-αI) onto HA, but that the presence 
of HC2 appeared to be necessary for this enzymatic 
action of TSG-6 to take place. 
There is a fourth HC (HC4) about which less is 
known.  It does not have the conserved cleavage site 
of HC1-3 that allows them to link with Bikunin.   It 
does, however, bind to and block the polymerization 
of actin, resulting in inhibition of neutrophil 
phagocytosis and chemotaxis (21).  The more 
recently described HC5 has not yet been fully 
characterised, nor shown to complex with CS to 
form IαI (or pre IαI).  It does, however, possess the 
necessary binding sites to enable it to do so (22) 
(Fig 1) The existence of HC6 was recently identified 
in Genebank from a report of 2003 (23) but no 
protein product has yet been described. 
In the current manuscript we have examined the role 
of TSG-6 following TGF-β1 stimulation and 
highlighted HC transfer activity as being key to 
form a HA matrix which is anchored by CD44 
leading to a CD44:EGF-R signalling complex.  This 
activity was specifically dependent on HC5.  We 
demonstrate for the first time that HC5 has a major 
mechanistic role to play in the phenotypic activation 
of fibroblasts. 
 
MATERIALS AND METHODS  
Materials. 
All reagents were from Sigma-Aldrich (Poole, UK) 
unless otherwise stated.. ERK (MEK) inhibitor 
PD98059 and EGF-R inhibitor AG1478 were 
purchased from Calbiochem (Darmstadt, Germany).  
They were prepared as stock solutions of 5 mg/ml 
and 3 mg/ml respectively.  Oligo HA (10 units; i.e. 
10 monosaccharides) (purchased from Hyalose, 
Oklahoma City; HYA-OLIGO10EF-1) and a 
hexasaccharide control (Iduron UK) were prepared 
at a concentration of 1 mg/ml, and was added to 
give a final concentration of 50 µg/ml on the cells 2 
h prior to stimulation with TGFβ.  Cobalt Chloride 
was stored at a concentration of 500 mM in PBS.   
All inhibitors were diluted immediately before use 
and added to the cell cultures at the times given in 
the legends before addition of TGF-β1. Anti IaI 
heavy chain 5 antibody ab107846 and anti IaI heavy 
chain 2 antibody ab118257 together with the 
loading control anti GAPDH antibody ab9485 were 
purchased from Abcam (Cambridge UK). 
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Cell Culture  
Primary human lung fibroblasts (AG02262; NIA 
Ageing Cell Respiratory Corriel Institute, NJ, USA) 
were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) and F-12 medium containing 2 
mM L-glutamine, 100 units/ml penicillin, and 100 
µg/ml streptomycin supplemented with 10% fetal 
calf serum (FCS) (Biologic Industries Ltd., 
Cumbernauld, UK). The cells were maintained at 
37°C in a humidified incubator in an atmosphere of 
5% CO2, and fresh growth medium was added to the 
cells every 3-4 days until confluence. Cells were 
growth arrested in serum-free medium for 48 hours 
before use in experiments, and all experiments were 
performed under serum-free conditions unless 
otherwise stated.  For the induction of 
differentiation cells were exposed to a single 
treatment of TGF-β1 at the concentrations indicated 
for times up to 72 hrs as in previous studies (12-14). 
 
Reverse Transcription (RT) and Real-Time 
Quantitative Polymerase Chain Reaction (QPCR-
RT)  
Cells were grown in 35 mm dishes and washed with 
phosphate-buffered saline (PBS), pH 7.3, prior to 
lysis with tri-reagent and RNA purification 
according to the manufacturer’s protocol. RNA was 
precipitated with isopropanol and washed with 70% 
ethanol before being dried and resuspended in 
water.  The concentration of RNA was determined 
by the absorbance at 260 nm.  Reverse transcription 
was performed on 1mg of RNA, using random 
primers to initiate cDNA synthesis with High 
Capacity cDNA reverse transcription kits, according 
to the manufacturer’s protocol (Applied Biosystems, 
Cheshire, UK). As a negative control, RT was 
performed with sterile H2O replacing the RNA 
sample. qPCR was carried out using a 7900HT Fast 
Real Time PCR System (Applied Biosystems, 
Cheshire, UK).  cDNA was diluted 4 fold and 4 ml 
(equivalent to 0.05 mg of the original RNA) was 
amplified in a final volume of 20 ml containing 
10 ml Taqman master mix (Applied Biosystems), 
5 ml H2O and 1 ml specific primer.  
The following primers were purchased from 
Applied Biosystems:- 
α-SMA primer ACTA2 Cat No 4331182 
Hs00426835_g1 
TSG-6 primer TNFAIP6 Cat No Hs00200180_m1 
rRNA was used as the internal control for all 
samples, and the results presented as the RQ 
calculated by the delta delta CT method using the 
equation: 2- [ΔCT(1)- ΔCT(2)]  (where ΔCT(1) is the mean 
ΔCT calculated for the experimental samples and 
ΔCT(2) is the mean ΔCT calculated for the control 
samples (Applied Biosystems, Cheshire, UK). 
 
Heavy chain amplification was carried out by qPCR 
of the cDNA with specific primers to each IaI heavy 
chain using SYBR Green  (Applied Biosystems). 
In selected experiments mRNA copy number was 
determined by amplifying each heavy chain by 
conventional PCR and calculating the number of 
molecules present in the purified amplified product. 
Serial dilutions from 300,000 to 30 copies were 
prepared for each heavy chain and the amplified 
qPCR signal of the experimental samples read off 
the standard curves produced. 
All oligonucleotide primers were purchased from 
Invitrogen (Paisley U.K.) 
The Inter-alpha Trypsin Inhibitor  Heavy chain 
(ITIH) qPCR primers used were: - 
ITIH1 F TCCATGGAGAACAACGGACG 
ITIH1 R GGGGGTACTGCAAATCCACA 
ITIH2 F GCCATTTCGATGGTGTTCCG 
ITIH2 R TTCTCTGCTGTGCTACCGTG 
ITIH3 F CCTTTCGGCTGCTTGGGAAA 
ITIH3 R GACGGCTCTCATGGTGACAA 
ITIH4 F AGTCACCAAACCCGATGACC 
ITIH4 R GCTCCAGCTGAGTGGACATT 
ITIH5 F ACTGTCGCTGGAGAACTGTG 
ITIH5 R CGGGGTCCTGATTTCATCGT 
ITIH6 F CATTGCATGGAAGCCGATGG 
ITIH6 R GGCTCCTGGTTGCTATGGTT 
 
The FnEDR qPCR primers used were: - 
FnEDR F GCTCAGAATCCAAGCGGAGA 
FnEDR R CCAGTCCTTTAGGGCGATCA 
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Inhibition by siRNA 
All siRNA was purchased from Life Technologies 
Ltd, Paisley. 
SiRNA (TSG-6) Cat.# M16704/s14263 
SiRNA (Bikunin)  Cat. # 4392420/s1311 
SiRNA (CD44)              Cat.#AM16704/114068 
SiRNA (ITIH5)  Cat.# 4392420/s37361 
SiRNA (ITIH2)  Cat. # 439 20/s7604 
SiRNA (Smad 2)           Cat.# M16704/107875 
SiRNA (Smad 3)           Cat.# M16704/115717 
 
Silencer® Negative Control No. 2 siRNA Cat. 
#AM4613 
Cells to be transfected were deprived of serum for 4 
h before the addition of the siRNA. Briefly, 
Lipofectamine 2000 (Invitrogen) was diluted 1/50 in 
Optimem (Gibco 31085) and allowed to stand for 5 
min.  This was then added to a 333 nM dilution of 
the siRNA prepared immediately before use from a 
100 µM stock.  The mixture was left at room temp 
for 30 min to allow the Lipofectamine:siRNA 
complexes to form, then 200 µl of this preparation 
was added to 800 µl of serum-free antibiotic-free 
medium on the cells to give a final concentration of 
33 nM and the transfection allowed to take place 
overnight. Control cells were transfected with 
scrambled siRNA. The following day the 
appropriate stimuli were added to the cells as 
described, without removing the siRNA complexes 
and the incubation continued for a further 72h 
(unless otherwise indicated) before isolating RNA.  
Typical knockdown ranges using these siRNA’s 
were SiTSG6, 51% to 60%; SiBikunin, 78% to 
89%; SiCD44, 53% to 67%; SiHC5, 89% to 98%; 
HC2, 90% to 99%.. 
 
 
SDSPAGE and Western Blotting 
Cells were cultured for 72h under the designated 
conditions before total cell protein was extracted in 
100 µl lysis buffer as previously described (24). 
Protein concentration was determined by the 
Bradford protein assay and 30 µg of each sample 
was boiled with reducing buffer for 10 minutes 
before being subjected to SDS-PAGE on a 7.5% 
acrylamide gel. Western blotting with rabbit anti-IαI 
HC5 primary antibody (Abcam, cat) was performed 
by standard methods to detect the presence of HC5. 
Detection was performed with a specific anti rabbit 
HRP conjugated antibody (Abcam Cat. 970510 and 
ECL reagent. Equal loading was confirmed by the 
use of anti GAPDH antibody (Abcam Cat 9485). 
Immunocytochemistry 
Cells were growth arrested before incubation with 
TGFβ1 (10ng/ml) or serum-free medium alone in 
the presence or absence of anti-TSG-6 Ab A38 
(Santa Cruz: sc-65886) at 50 µg/ml. After 72h cells 
were fixed with 4% paraformaldehyde at room 
temperature for 15min.  Fixed cells were stained for 
EGF-R (Abcam GR01 1:30), visualised using 
AlexaFluor 488) and CD44 (Ab A020 1:200) 
(Merck Millipore), visualised with AlexaFluor 555).  
The images were merged to demonstrate the co- 
localisation of CD44 and EGF-R. 
 
The unpaired two-tailed Student’s t-test was used to 
identify statistical significance. Data were analysed 
using the software GraphPad Prism version 4.0a 
(GraphPad Software Inc., La Jolla, CA, USA) and 
*P≤ 0.05 and **P≤ 0.01 were considered 
significant. 
 
 
RESULTS 
In  association between induction of TSG-6 and 
phenotypic activation of fibroblasts 
TSG-6 has been shown to be essential for the 
TGFβ1-dependent phenotypic activation of 
fibroblasts and renal epithelial cells (14, 16, 25).  In 
order to determine the temporal relationship 
between TSG-6 expression and induction of the 
myofibroblast phenotype, growth arrested 
fibroblasts were stimulated with TGF-β1 (10 ng/ml) 
and mRNA was extracted at times up to 72 hours.  
Addition of TGF-β1, led to a time-dependent 
induction of TSG-6 that was significant at 3 h, 
reached a maximum at 8 h and was sustained to 72 
h. In contrast the induction of the phenotypic 
markers, alpha-sma and the EDA isoform of 
fibronectin (fnEDA), was slower, becoming 
significant at 24 h and continuing to increase up to 
72 h.  There was no significant change in the levels 
of Bikunin over this time-course (Fig 2). These 
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results suggest but do not confirm, in themselves, a 
temporal separation between TSG-6 up-regulation 
and induction of phenotypic activation. 
To investigate whether the induction of TSG-6 and 
alpha-sma were both triggered by a CD44-
dependent mechanism, siRNA was used to 
knockdown CD44 expression.  This resulted in 
>50% inhibition of CD44 protein expression 
(Fig3A), which was associated with a 60% 
inhibition of alpha-sma mRNA (Fig 3B) as reported 
previously (14, 23, 26).  Knocking down CD44, 
however, had no inhibitory effect on TSG-6 
expression (Fig 3C).  The change of phenotype in 
response to TGF-β1 is also, however, dependent on 
EGF-R activation (14).  Following inhibition of 
EGF-R activity by AG 1478, α-sma induction was 
inhibited by >99% (Fig 3D), TSG-6 expression, 
however, was unaffected (Fig 3E).   
Phosphorylation of ERK 1&2 is downstream from 
the EGFR-CD44 interaction.  To confirm that TSG-
6 was not induced as a result of this signalling 
pathway, ERK activation by MEK was inhibited 
using PD98059. This inhibited α-sma induction by 
approximately 60% but TSG-6 was again unaffected 
(Fig 3 F&G).  Taken together these results indicate 
that TSG-6 was not induced by the same series of 
activation events as those leading to phenotypic 
change and, together with our previous work (14, 
16, 24) that it may, therefore lie upstream of 
formation of the EGF-R:CD44 complex.   
Induction of TSG-6 is Smad dependent 
Although induction of HA and HA synthase is 
dependent on TGF-ß1 activation of ERK and 
subsequently the EGF-R, classical TGF-ß1 
signalling is initiated when the ligand induces 
assembly of a heteromeric complex of type II and 
type I receptors.  The RII kinase then 
phosphorylates RI on a conserved glycine-serine 
rich domain.  This activates the RI kinase, which 
subsequently recognises and phosphorylates 
members of the intracellular receptor regulated 
Smads  (Smad2 and Smad3).  Smad signalling 
through the activation of this classical pathway has 
previously been implicated in phenotypic activation 
of fibroblasts, through the use of chemical inhibition 
of the ALK5 receptor (26).  The role of Smad 
signalling was examined by gene silencing of either 
Smad 2 or Smad3 using siRNA.  The siRNA to 
Smad2 caused between 60% and 70% knockdown 
of Smad2 in these cells with the siSmad 3 giving 
between 50% and 60% knockdown of Smad3 (Fig 
4).  Smad gene knockdown inhibited TGF-ß1 
dependent induction of TSG-6 and phenotypic 
activation, reflected by an inhibition of TGF-ß1 
induction of the myofibroblast marker, alpha-sma 
(Fig 4 A and B). These data therefore suggest that 
both Smad dependent and independent pathways are 
required for phenotypic activation, with the Smad 
pathway alone leading to induction of TSG-6, which 
is distinct from the signalling pathway leading to 
HA synthesis and HA-dependent signalling.   
The mechanism of TSG-6 action in phenotypic 
activation of fibroblasts 
TSG-6 binds directly to HA through its link module.  
In addition, by a separate mechanism, TSG-6 also 
supports the covalent transfer of heavy chains (HCs) 
of the IαI family members to HA, both of which 
roles are likely to stabilise HA matrices.  The IαI 
family exists as a distinct assembly of one bikunin 
chain with one or more unique heavy (HC) chains 
designated HC1, HC2, HC3, HC5 and HC6 (HC4 
does not bind bikunin).  Covalent transfer of heavy 
chains to TSG-6 requires the bikunin component of 
IαI and is irreversibly inhibited by Cobalt (19). 
Gene silencing of Bikunin significantly inhibited 
TGF-β1-dependent phenotypic activation of 
fibroblasts, as did the presence of 1 mM cobalt (Fig 
5 A&C).  Neither intervention influenced TGF-β1-
dependent induction of TSG-6 (Fig 5 B&D).  TSG-6 
function has been previously shown to be inhibited 
by the rat anti-human TSG-6 monoclonal antibody 
A38, which blocks HC binding to TSG-6 (27) and 
inhibits the formation of TSG-6-HC complexes in 
vitro (28).  Similarly, HA decasaccharides (Oligo 
HA) irreversibly compete with HC binding to HA, 
preventing HA assembly, while hexasaccharides are 
ineffective.  Stimulation of fibroblasts with TGFβ1 
in the presence of either Oligo HA, to prevent HA 
binding by HC (Fig 5 E&F), or of the A38 antibody, 
at a concentration previously demonstrated to inhibit 
TSG-6 activity in vitro (16) (Fig 5 G&H), inhibited 
phenotypic activation, without affecting TGF-β1 
induction of TSG-6.  These data suggest that the 
function of TSG-6 that is critical for phenotypic 
activation is covalent transfer of heavy chains of IαI 
to HA which subsequently forms an organised and 
stable HA matrix.   
To confirm that TSG-6-dependent covalent heavy 
chain transfer onto HA was required to drive 
receptor co-localisation, fibroblasts were stimulated 
with TGFβ1 in the presence of the A38 antibody.  
After 72 hours cells were dual-labelled for CD44 
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(red) and EGF-R (green).  The results demonstrate 
an increased association of CD44 and EGF-R 
(yellow) following TGF-β1 stimulation, which was 
inhibited by the presence of the anti-TSG-6 A38 
antibody (Figure 6).  These results are therefore 
consistent with TSG-6 mediated heavy chain 
stabilisation of the HA matrix driving CD44 – EGF-
R co-localisation.  The phenotypic change triggered 
by TGF-β1 is therefore dependent on the induction 
of TSG-6, which, through catalytic transfer of IaI 
HCs, orchestrates HA-dependent CD44-EGFR 
interactions and triggers downstream ERK 
signalling pathways. 
 
The heavy chain 5 of inter-alpha-inhibitor is highly 
expressed by fibroblasts and is linked to 
myofibroblast formation. 
In order to investigate the role of each of the heavy 
chains of IαI in phenotypic activation, qPCR was 
performed for each of the chains HC1 to HC6. All 
of the chains were expressed and repeated analysis 
to obtain absolute values for the copy numbers of 
each transcript showed that HC5 was consistently 
very highly expressed compared to minimal 
expression of either HC1 or HC2 (Fig 7A).  HC1 
and HC2 proteins were not detected on the cells 
either by immunocytochemistry or Western blotting 
of cell lysates (not shown).  In contrast, HC5 protein 
expression was examined by Western blot of cell 
lysates and, while low in unstimulated cells, it was 
strongly induced by TGF-β1 treatment (Fig 7B).  
Following treatment of the fibroblasts with a low 
concentration of trypsin before lysis, HC5 became 
undetectable by Western blot, suggesting that the 
majority of the HC5 detected in the original lysates 
was extracellular and associated with the cell 
surface.   Cell surface expression of HC5 was 
confirmed by immunocytochemistry in both 
untreated and TGF-β1-treated cells (Fig 7C) and 
was reduced by exposure of the cells to 
Streptomyces hyaluronidase  
The data generated above all suggest the importance 
of interactions between TSG-6 and HC5 for 
controlling the change in phenotype of the 
fibroblasts.  To investigate whether these proteins 
could be found in higher molecular weight 
complexes, supernatants from the cells incubated in 
serum-free medium or treated with TGF-β1 were 
probed for TSG-6, HC5 and Bikunin.  TGF-β1 
induced the expression of all three proteins in the 
cell supernatants (Fig 8 A) and they were all also 
present as components of higher molecular weight 
complexes.  Treatment of supernatants with 
Chondroitinase ABC resulted in a reduction of 
HC5-containing complexes (molecular weight 100-
130 kDa, approximately), without affecting the non-
complexed HC5 band, confirming that HC5 is 
present in IαI complexes with Bikunin. 
To confirm the importance of TSG-6 in making 
HC5 an integral part of the pericellular HA matrix, 
cells were treated with siTSG-6 then lysed and 
Western blot performed for HC5 (Fig 9A).  There 
was a marked reduction in HC5 levels similar to the 
effect of direct knockdown of HC5 (Fig 9b), when 
compared to treatment with scrambled control or 
siHC2 (Fig 9C). Treatment with siBikunin also 
markedly reduced HC5 levels, suggesting that HC5 
must be part of an IaI or pre-aI complex to be 
functional (Fig 9D).  To confirm that active TSG-6 
was needed for HC5 incorporation into the 
pericellular matrix, cells were treated with, oligo 
HA (Fig 9E), Cobalt (Fig 9F) or mab A38 (Fig 9G).  
All reduced HC5 protein levels markedly. To 
examine the mechanisms holding HC5 at the cell 
surface, cells were treated with hyaluronidase (Fig 
9H) or with si CD44  (Fig 9I).  Both treatments 
reduced HC5 levels detected by Western blot, 
demonstrating that an association with HA and the 
presence of this HA binding receptor were essential 
for anchoring HC5 at the cell surface. 
HC5 knockdown was used to investigate the 
functional significance of the HC5 associations at 
the cell surface described above. Knockdown of 
HC5 was >95% (Fig 10A) and resulted in a 
reduction in TGF-β1-simulated alpha-sma 
expression of >50% (Fig 10B).  There was no effect 
of knockdown on TSG-6 expression (Fig 10C), 
confirming the independence of the HA-dependent 
differentiation pathway and the TSG-6 induction 
pathway. 
 
DISCUSSION 
Hyaluronan is a ubiquitous connective tissue 
glycosaminoglycan that, in vivo, is present as a 
high-molecular mass component of the extracellular 
matrix.  In addition to its role in providing cellular 
support, it is known that under normal 
circumstances, HA regulates cell-cell adhesion, 
migration, proliferation, differentiation and the 
movement of interstitial fluid and macromolecules 
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(reviewed in 29)  As a result it is likely to be an 
important contributor to and a regulator of, tissue 
remodelling.  Our primary interest is understanding 
the pathogenesis of progressive fibrosis particularly 
in the context of renal disease.  In a study of patients 
with biopsy proven diabetic nephropathy we have 
previously demonstrated an association between the 
deposition of hyaluronan and the degree of renal 
fibrosis, which is a known predictor of clinical 
outcome (30).  This led us to examine the role of 
HA in regulation of fibroblast phenotype.   
We have demonstrated that the phenotypic effects of 
TGF-β1 in fibroblasts are orchestrated by its 
stimulation of HA synthesis and accumulation in a 
pericellular coat (12, 13, 14, 26).  The formation of 
this coat and the resulting change in cell phenotype 
is shown in this study to be dependent on the 
induction and activity of the hyaladherin, TSG-6.  
Inhibition of TSG-6 expression or its HC-transfer 
ability strongly inhibited the phenotypic change of 
fibroblasts to myofibroblasts.  Many cell types 
assemble HA in an organized pericellular coat in 
vitro, in which the HA is anchored to the cell-
surface by CD44 (16, 31, 32, 33, 34 35). Our recent 
studies in proximal tubular epithelial cells have 
investigated the roles of the IαI family of 
hyaladherin proteins, together with TSG-6 and the 
HA-binding proteoglycans bikunin and versican in 
the macro-molecular assembly of HA by PTC (16, 
25, 35, 36). The results demonstrated that the TSG-
6-mediated formation of IαI HC-HA complexes was 
critical for the formation of a pericellular HA 
matrix.  
The data included in this manuscript suggest that it 
is the HC:HA catalytic activity of TSG-6 that is the 
key for the phenotypic activation of fibroblasts.  
Both TSG-6:HC formation and the subsequent HC 
transfer onto HA are metal ion-dependent.  Previous 
studies have demonstrated the reaction to be 
dependent on either Mg2+ or Mn2+ and to be 
inhibited by Co2+ (19).  Inhibition of TGF-β1 
dependent phenotypic activation without any effect 
on the induction of TSG-6 itself is therefore 
consistent with a HC transfer function of TSG-6 
orchestrating matrix assembly and phenotypic 
activation. This is further supported by the 
inhibition of phenotypic activation by the 
stimulation of fibroblasts with TGF-β1 in the 
presence of the rat anti human monoclonal antibody 
A38.  This antibody has previously been 
demonstrated to block HA binding to TSG-6 (27), 
and inhibit the formation of TSG-6:HCs complexes 
in vitro (28).  The transfer of HC, requires an intact 
IaI protein, as evidenced by female mice lacking the 
bikunin gene, which express the HCs but are unable 
to assemble IaI/preaI and which do not form 
cumulus-oocyte HC/HA complexes (37, 38).  Our 
data using bikunin RNA silencing to inhibit the 
phenotypic activation of fibroblasts is therefore 
again compatible with the HC transfer catalytic 
activity of TSG-6 being a key component of 
acquisition of the myofibroblast phenotype.   
TSG-6 mediated organisation of the HA matrix has 
been reported previously to alter the interaction of 
HA with its principle cell surface receptor CD44.  
For example in solution, TSG-6/HA complexes 
enhance or induce binding of HA to cell surface 
CD44 (39).  It is well established that an organised 
pericellular HA coat is anchored to cell surface 
CD44 (34). We have previously demonstrated that 
phenotypic activation of fibroblasts requires HA 
driven formation of CD44-EGF-R complexes, and 
this together with the data in this manuscript 
suggests that TSG-6-dependent HC:HA interactions 
lead to the formation of a pericellular HA matrix 
which facilitates CD44 re-localisation within the 
cell membrane.  This receptor complex then 
activates a downstream signalling cascade which is 
responsible for re-organisation of the actin 
cytoskeleton (24).   
While this study demonstrates the importance of 
TSG-6-dependent HC:HA interactions, rather than 
the well-described HC1-3 involvement seen in 
epithelial cells, the essential and necessary HC for 
triggering HA transfer and the phenotypic change in 
fibroblasts was HC5.  Its importance was further 
emphasised by the fact that in cell supernatants HC5 
was only found in high molecular weight complexes 
and not as a monomer.  In addition, while the 
mRNA levels of HC5 decrease following TGF-β1 
treatment, the cell-associated protein levels increase, 
suggesting that the most important regulation of 
HC5 is not transcriptional but post-transcriptional 
through its incorporation into the HA pericellular 
matrix of the cell.   
HC5 plays a role in tumour suppression with 
dysregulated or reduced expression of HC5 directly 
linked to tumour development (22, 40, 41) and its 
overexpression leading to suppression of cell 
migration and colony spreading (42).  A recent 
study also found that HC5 was the major heavy 
chain expressed in skin, predominantly due to its 
production by dermal fibroblasts (43). The authors 
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conclude that HC5 may play an important role in 
inflammation through its interaction with HA.  To 
our knowledge this report of Huth et al is the first 
description of a role for HC5 outside the area of 
tumourigenesis and metastasis and adds to the 
important role for HC5 described in our current 
study.   
In summary, much has been previously published on 
the anti-inflammatory role of the hyaladherin TSG-
6.  The data in this manuscript provide evidence that 
it is also involved in driving a pro-fibrotic response 
through its catalytic transfer of HC5 to HA and that 
the mechanisms regulating TSG-6 and HA synthesis 
during this pro-fibrotic, TGF-β1-dependent process 
are distinct.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FOOTNOTES 
Abbreviations!Used:!
!
TGF;β1! ! Transforming!Growth!Factor;β1!
α;sma!!! ! α;smooth;muscle!actin!
EGFR!! ! ! Epidermal!Growth!Factor!Receptor!
IαI!! ! ! Inter;alpha;Inhibitor!
TSG;6! ! ! Tumour!Necrosis!Factor;stimulated!gene;6!!
HC!! ! ! IαI!heavy!chain!!
HA! ! ! Hyaluronan!!
CS! ! ! Chrondroitin!sulphate!!
4!MU! ! ! 4;methyl;umbelliferone!!
DMSO! ! ! diMethylsulphoxide!
FCS    Fetal calf serum  
RT    Reverse Transcription  
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QPCR-RT  Real-Time Quantitative Polymerase Chain Reaction  
 
PBS   Phosphate-buffered saline  
SDSPAGE   Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
FnEDR   EDA!isoform!of!fibronectin!
Oligo!HA(6!or!10)! Hyaluronan!oligosaccharides!(6!or!10!monosaccharide!units) 
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LEGENDS 
Figure 1 
The sequences of all six of the IαI heavy chains were obtained from Genebank and aligned using 
MegAlign software. The sequences of the putative binding sites of the heavy chains to chondroitin 
sulphate to form IαI are highlighted in the blue box.  It can be seen that the sequence of HC4 is uniquely 
distinct from the other heavy chains at this site. 
 
Figure 2 
Human lung fibroblasts were growth arrested and were then stimulated with TGF-β1 (10 ng/ml). The RNA 
was collected at the times shown and the RQ of alpha sma, FnEDA, Bikunin (Bik) and TSG-6 were 
determined by RTqPCR. Data shown are the mean ± SEM of five independent experiments, each of which 
generated a mean of 3 replicates.  * p<0.05,   ** p<0.005 compared to 0 hrs. 
 
Figure 3 
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Human lung fibroblasts were growth arrested and were then stimulated with TGF-β1 (10 ng/ml). The RNA 
was collected after 72h treatment and the RQ of alpha sma (B,D,F), and TSG-6 (C,E,G) were determined 
by RTqPCR. The panels show cells (A) treated with siCD44, lysed and protein extracted for CD44 
Western Blot; (B) and (C) si-CD44. (D) and (E) EFGR inhibitor AG 1478 (10 µM). (F) and (G) ERK 
inhibitor PD98059 (10 µM).  Inhibitors were added 4 h prior to TGFβ1 stimulation.  Data shown are the 
mean and scatter of values in three independent experiments, each with between 2 and 3 replicates, except 
(D) and (E)- 1 experiment with 3 replicates.  * p<0.05,   ** p<0.005 compared to TGF-β1 treatment alone. 
 
Figure 4 
Confluent fibroblasts were growth-arrested in serum-free medium for 48 hours, then treated with either 
scrambled siRNA or siRNA specific for Smad 2 or Smad 3 as detailed in Methods. The cells were then 
incubated with TGF-β1 at 10 ng/ml in serum-free medium for 72 hours.  Control cells remained in serum-
free conditions, without TGFβ1. The cells were lysed, RNA extracted and RTqPCR for (A) alpha-sma or 
(B) TSG-6, carried out as described in Methods. Results are expressed as mean and scatter of values in two 
independent experiments, each with 2 or 3 replicates (*p<0.05, compared to Scrambled). Scrambled in (A) 
and (B) was independently analysed more frequently.  (C) and (D) show the inhibition of SMAD2 and 
SMAD3 by siSMAD2 or siSMAD3 respectively in 3 independent experiments. 
 
Figure 5 
Human lung fibroblasts were growth arrested and were then stimulated with TGF-β1 (10 ng/ml).  The 
RNA was collected after 72h treatment and the RQ of alpha sma (A,C,E,G), and TSG-6 (B,D,F,H) were 
determined by RTqPCR. The panels show cells treated 4 h before TGFβ1 stimulation with:-   (A and B) si-
Bikunin,  (C and D) Cobalt Chloride (0.05 mM to 1 mM),  (E and F) Oligo HA (at 50 µg/ml), (G and H) 
anti-TGS-6 antibody A38 and non-immune IgG control ((50 µg/ml).  Data shown are the mean and scatter 
of values in three independent experiments, each with more than 2 replicates.  * p<0.05,   ** p<0.005 
compared to scrambled (A and B) or TGFβ1-stimulated cells (C-H). 
 
Figure 6 
Human lung fibroblasts were growth arrested and were then either incubated with TGF-β1 (10 ng/ml) or 
serum-free medium alone in the presence (A38) or absence of anti-TSG-6 antibody A38 at 50 µg/ml. Cells 
were stained for EGFR (Ab GR01 1:30), visualised using AlexaFluor 488) and CD44 (Ab A020 1:200) 
(Merck Millipor), visualised with AlexaFluor 555).  The images were merged to demonstrate the co- 
localisation of CD44 and EGFR (yellow).  Nuclei were stained with DAPI and the central images show a 4 
times magnification of sections of the images.  Co-localization scatter plots were performed to confirm co-
localization (depicted as yellow areas).  Data shown are representative of three independent experiments. 
Figure 7 
A)  The absolute copy number of each IαI heavy chain was determined by reading standard curves 
prepared by adding known numbers of molecules to the qPCR reaction. Heavy chain 5 was shown to be 
the predominant isoform.  Results are mean ± SEM of 4 independent experiments. 
B)  Human lung fibroblasts were growth arrested and were then cultured in the presence or absence of 
TGF-β1 (10 ng/ml) for 72h.  The cells were lysed with RIPA buffer and 30 µg of protein was separated on 
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7.5% polyacrylamide gels. GAPDH antibody was used as a loading control. Blots shown are representative 
of 4 experiments. 
 Top panel: Western blot showing that the amount of IaI heavy chain 5 present was markedly increased 
following stimulation with TGF-β1 Bottom Panel: Following TGF-β1 incubation the cells were treated 
with 10 µg/ml trypsin in PBS for 10 min at room temperature as previously shown to remove any cell 
surface/CD44-associated HA (43).  
C)  Cells were incubated with or without TGF-β1 (10 ng/ml) for 72h.  The cells were then either left 
untreated or exposed to Streptomyces hyaluronidase (0.4 U in 400 µl PBS for 2h).  All cells were then 
fixed with 4% paraformaldehyde in PBS for 20 min and stained with anti-HC5 antibody followed by FITC 
conjugated anti rabbit IgG in order to demonstrate the presence of heavy chain 5 on the cell surface.  Data 
shown are representative of three independent experiments. 
 
Figure 8 
Human lung fibroblasts were growth arrested and were then in the presence (+) or absence (-) of TGF-β1 
(10 ng/ml) for 72h. (A) The culture supernatant was collected and concentrated using Micron centrifugal 
filter (Millipore) with a 3 kDa cut off. The equivalent of 1 ml of supernatant was then loaded into each 
well of a 7.5% polyacrylamide gel. Western blotting was carried out to demonstrate the presence of the 
native proteins and higher molecular weight complexes of TSG-6, Bikunin and Heavy Chain 5.  (B) 
TGFβ1-treated cells were lysed and split into two identical samples of 30 µg. One half was treated with 
chondroitinase ABC (0.166 U/ml; Sigma-Aldrich) and both samples were incubated at 37 °C over night. 
The samples were then separated on a 7.5% polyacrylamide gel and Western blotting was carried out using 
anti-HC5 in order to demonstrate the degradation of the higher molecular weight complexes 
containing Heavy Chain 5.  All blots in A and B are representative of 3 independent experiments. 
Figure 9 
Human lung fibroblasts were growth arrested and were then stimulated with TGF-β1 (10 ng/ml) or placed 
in serum-free medium only (Con) for 72h. The cells were then lysed (150 µl RIPA buffer per well of a six 
well plate), and 30 µg was separated on a 7.5% polyacrylamide gel. They were then subjected to Western 
blotting for HC5 with GAPDH used as a loading control. Blots shown are representative of 4 independent 
experiments. 
A-D) Cells were cultured in the absence (-) or presence (+) of TGF-β1 (10 ng/ml) plus either Scrambled 
siRNA (scr), or target-specific siRNA: A) siTSG-6, B) siHC5, C) siHC2, D) siBikunin  
E-I) Cells were cultured in the absence (Con) or presence of TGFβ1 (10 ng/ml) together with either E) 
oligosaccharides of HA, F) cobalt chloride (1 mM), G) mAb A38 (50 µg/ml), compared to non-immune 
IgG, or H) Streptomyces hyaluronidase (0.4 U in 400 µl PBS for 2h).  siCD44 was also used as above to 
specifically knockdown CD44 compared to scrambled control (Fig I) as above (A-D). 
 
Figure 10 
Human lung fibroblasts were growth arrested and were then stimulated with TGF-β1 (10 ng/ml) in the 
presence or absence of SiHC5. The RNA was collected after 72h incubation and the effect of SiHC5 on 
copy number of heavy chain 5 (A) and the RQ of alpha sma (B), or TSG-6  (C) were determined by 
RTqPCR.  Data shown are mean and scatter of values from three independent experiments.  * p<0.05    ** 
p<0.005 for siHC5 compared to scrambled. 
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